Description
Glimepiride, Pioglitazone & Metformin Hydrochloride Tablets
Healthy Inc is a specialized global supplier and exporter of advanced endocrinology, metabolic health, and internal medicine therapeutics. We provide ultra-high-purity, kinetically stable Triple-Combination Anti-Diabetic Tablets, manufactured in WHO–GMP certified, high-precision pharmaceutical facilities. This “Synergistic Hypoglycemic Combination” is a massive-volume strategic export to endocrinology clinics, government health programs, and international B2B distributors, serving as the globally preferred intervention for patients requiring intensified glycemic control.
Product Overview
This formulation operates as a “Total Glycemic Regulator.” It ensures patient safety by targeting insulin resistance, insulin secretion, and glucose production simultaneously in a single Fixed-Dose Combination (FDC).
Mechanism 1 (Insulin Secretagogue – Glimepiride): Glimepiride physically binds to ATP-sensitive potassium channels in pancreatic beta cells. This chemically triggers the physical release of stored insulin into the bloodstream.
Mechanism 2 (Insulin Sensitizer – Pioglitazone): Pioglitazone physically activates PPAR-gamma receptors in adipose and muscle tissue. This chemically improves the body’s physical sensitivity to insulin, allowing cells to absorb glucose more efficiently.
Mechanism 3 (Hepatic Glucose Inhibitor – Metformin): Metformin physically activates AMPK. This chemically suppresses the liver’s physical production of glucose (Gluconeogenesis) and slows glucose absorption in the intestines.
Product Composition & Standard Strengths
We supply this product in standardized Fixed-Dose Combinations (FDCs) designed for flexible clinical titration.
| Active Ingredient | Common Strength | Primary Clinical Function |
| Metformin HCl (SR/IR) | 500 mg / 1000 mg | The Foundation: Reduces glucose production. |
| Glimepiride | 1 mg / 2 mg | The Stimulator: Enhances insulin secretion. |
| Pioglitazone | 15 mg | The Sensitizer: Fixes insulin resistance. |
Technical & Logistics Specifications
HS Code: 3004.90.99 (Medicaments acting on the metabolic system / Others)
CAS Numbers: 93479-97-1 (Glimepiride) / 111025-46-8 (Pioglitazone) / 1115-70-4 (Metformin)
Dosage Form: Oral Tablet (often utilizing Sustained Release/SR Metformin)
Packaging: 10 or 15 Tablets per Blister in high-barrier Alu-Alu (Cold-Form Foil). Our specialized packaging ensures 36-month stability in Zone IVb tropical climates.
Manufacturing Authority & Compliance
Triple-API Stability: Combining three distinct chemical classes is physically complex. Our manufacturing process utilizes Multi-Layer Tableting or Specialized Granulation, physically ensuring the three drugs do not chemically interact or degrade within the tablet.
Modified Release Engineering: We utilize Hydrophilic Matrix Systems for the Metformin component, physically ensuring a slow, chemical release that physically minimizes gastrointestinal side effects—a critical commercial advantage.
Content Uniformity: We utilize Automated High-Speed Compression, physically ensuring that the low-dose Glimepiride (1mg/2mg) is chemically uniform across every tablet in a high-volume batch.
Primary Indications
Endocrinology: Second or third-line treatment of Type 2 Diabetes Mellitus.
Metabolic Syndrome: Management of patients physically struggling with both high blood sugar and severe Insulin Resistance.
Patient Compliance: Ideal for reducing “pill burden” in chronic diabetic management.
Usage Instructions
Administration: Swallow the tablet physically whole with water. Do not crush or chew SR (Sustained Release) variants.
Timing: It is physically critical to take this medication with or immediately after the first main meal of the day. This chemically optimizes glucose control and physically reduces stomach upset.
Hypoglycemia Awareness: Because it contains Glimepiride, patients should physically carry a source of sugar in case of a chemical drop in blood sugar (Hypoglycemia).
Monitoring: Regular HbA1c and Blood Glucose monitoring is physically required to assess chemical efficacy.
Safety Warning: For Oral Use Only. Lactic Acidosis: Rare but severe physical risk associated with Metformin; monitor renal function chemically. Edema Note: Pioglitazone may physically cause fluid retention; use with caution in heart failure patients. Contraindication: Do not use in patients with Type 1 Diabetes, severe renal or hepatic impairment, active bladder cancer, or known hypersensitivity to any of the ingredients.
Global Export & Contract Manufacturing
Healthy Inc is a premier Anti-Diabetic and Metabolic Health Pharmaceutical Exporter in India. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) for high-volume Triple-Combination tablets. Whether you are a National Diabetes Program in the CIS or a B2B Pharma Marketplace partner in Africa or SE Asia, we ensure secure, WHO-GMP compliant delivery.
Commercial Inquiries:
WhatsApp/Call: +91 7710003340
Email: info@healthyinc.co.in
